Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial

OBJECTIVE: To report the 2‐year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular‐course juvenile idiopathic arthritis (JIA). METHODS: Patients ages 2–17 years with active polyarticular‐course JIA, in whom treatment with methotrexate was unsuccessful, received 16 weeks of open‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunner, Hermine I., Ruperto, Nicolino, Zuber, Zbigniew, Cuttica, Rubén, Keltsev, Vladimir, Xavier, Ricardo M., Burgos‐Vargas, Ruben, Penades, Inmaculada Calvo, Silverman, Earl D., Espada, Graciela, Zavaler, Manuel Ferrandiz, Kimura, Yukiko, Duarte, Carolina, Job‐Deslandre, Chantal, Joos, Rik, Douglass, Wendy, Wimalasundera, Sunethra, Bharucha, Kamal N., Wells, Chris, Lovell, Daniel J., Martini, Alberto, de Benedetti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Pediatric Rheumatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986602/
https://www.ncbi.nlm.nih.gov/pubmed/32951358
http://dx.doi.org/10.1002/art.41528

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986602/
https://www.ncbi.nlm.nih.gov/pubmed/32951358
http://dx.doi.org/10.1002/art.41528

Ejemplares similares